Location History:
- Emerald Hills, CA (US) (2020 - 2022)
- San Carlos, CA (US) (2022)
Company Filing History:
Years Active: 2020-2025
Title: Gregory Coffey: Innovator in Hematologic Cancer Treatment
Introduction
Gregory Coffey is a prominent inventor based in Emerald Hills, CA (US). He has made significant contributions to the field of hematologic cancer treatment, holding a total of 5 patents. His work focuses on innovative therapies that address various types of malignancies.
Latest Patents
Coffey's latest patents include groundbreaking methods for treating B-cell malignancies. One of his notable inventions is Cerdulatinib, which is designed for the treatment of relapsed or refractory hematologic cancers. The method involves administering a daily dose of Cerdulatinib, ranging from about 10 mg to about 75 mg, to patients suffering from conditions such as chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL). Another significant patent involves the use of Cerdulatinib for treating multiple myeloma (MM), acute myeloid lymphoma (AML), or myeloproliferative diseases (MPD), emphasizing the importance of effective treatment options for patients in need.
Career Highlights
Throughout his career, Gregory Coffey has worked with notable companies in the pharmaceutical industry. He has been associated with Alexion Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc., where he has contributed to the development of innovative therapies. His expertise in the field has positioned him as a key figure in advancing cancer treatment.
Collaborations
Coffey has collaborated with talented individuals in the industry, including Jiajia Feng and Andrew Steele. These partnerships have further enhanced his research and development efforts, leading to significant advancements in cancer therapies.
Conclusion
Gregory Coffey's contributions to the field of hematologic cancer treatment through his patents and collaborations highlight his dedication to improving patient outcomes. His innovative approaches continue to pave the way for new therapeutic options in oncology.